Peter Greenleaf
Chief Executive Officer at Aurinia Pharmaceuticals Inc
Sits on 3 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 3 boards, counting each seat separately. Longest: Aurinia Pharmaceuticals Inc, 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Pelthos Therapeutics Inc. December 17, 2025100.0%
-
Aurinia Pharmaceuticals Inc May 15, 202576.9%
-
Aurinia Pharmaceuticals Inc June 14, 202448.2%
-
Aurinia Pharmaceuticals Inc May 17, 202360.1%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 2, 2026 | Pelthos Therapeutics Inc. | Open-market sale | −797 | $21.17 | $16,872 |
| Jul 2, 2026 | Pelthos Therapeutics Inc. | Open-market sale | −712 | $26.00 | $18,512 |
| Jul 2, 2026 | Pelthos Therapeutics Inc. | Open-market sale | −85 | $27.27 | $2,318 |
| Apr 2, 2026 | Pelthos Therapeutics Inc. | Open-market sale | −420 | $20.52 | $8,618 |
| Apr 2, 2026 | Pelthos Therapeutics Inc. | Open-market sale | −377 | $21.36 | $8,053 |
| Mar 2, 2026 | Aurinia Pharmaceuticals Inc | Shares withheld for tax | −100,890 | $14.21 | $1,433,647 |
| Feb 27, 2026 | Aurinia Pharmaceuticals Inc | Grant or award | +196,403 | — | — |
| Feb 20, 2026 | Aurinia Pharmaceuticals Inc | Shares withheld for tax | −100,171 | $14.40 | $1,442,462 |
| Jan 2, 2026 | Aurinia Pharmaceuticals Inc | Grant or award | +165,384 | — | — |
| Jan 2, 2026 | Aurinia Pharmaceuticals Inc | Shares withheld for tax | −113,169 | $15.95 | $1,805,046 |
| Mar 4, 2025 | Aurinia Pharmaceuticals Inc | Open-market sale | −164,947 | $7.92 | $1,306,380 |
| Mar 3, 2025 | Aurinia Pharmaceuticals Inc | Grant or award | +333,705 | — | — |
| Mar 3, 2025 | Aurinia Pharmaceuticals Inc | Open-market sale | −195,593 | $8.00 | $1,564,744 |
| Feb 28, 2025 | Aurinia Pharmaceuticals Inc | Grant or award | +290,728 | — | — |
| Mar 6, 2024 | Aurinia Pharmaceuticals Inc | Open-market sale | −126,981 | $5.60 | $711,094 |
Questions about Peter Greenleaf
What boards is Peter Greenleaf on?
Peter Greenleaf sits on the boards of Altimmune Inc., Aurinia Pharmaceuticals Inc and Pelthos Therapeutics Inc.
What company is Peter Greenleaf the CEO of?
Peter Greenleaf is Chief Executive Officer of Aurinia Pharmaceuticals Inc.
How long has Peter Greenleaf served on boards?
Our records show at least 5 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.